11.57 USD
0 (0%)
11.45 USD
-0.12 (-1.04%)
VREX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While VREX seems to be doing ok healthwise, there are quite some concerns on its profitability. VREX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VREX was profitable.
In the past year VREX had a positive cash flow from operations.
In multiple years VREX reported negative net income over the last 5 years.
In the past 5 years VREX always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -12.34%, VREX perfoms like the industry average, outperforming 58.51% of the companies in the same industry.
The Return On Equity of VREX (-29.10%) is comparable to the rest of the industry.
With a decent Return On Invested Capital value of 5.07%, VREX is doing good in the industry, outperforming 77.13% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for VREX is below the industry average of 8.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.34% | ||
| ROE | -29.1% | ||
| ROIC | 5.07% |
ROA(3y)0.83%
ROA(5y)-0.21%
ROE(3y)1.75%
ROE(5y)-0.79%
ROIC(3y)5.22%
ROIC(5y)N/A
1.3 Margins
VREX has a Operating Margin of 7.00%. This is in the better half of the industry: VREX outperforms 72.34% of its industry peers.
In the last couple of years the Operating Margin of VREX has declined.
The Gross Margin of VREX (34.06%) is worse than 72.87% of its industry peers.
VREX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7% | ||
| PM (TTM) | N/A | ||
| GM | 34.06% |
OM growth 3Y-20.79%
OM growth 5Y-6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
VREX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for VREX has been increased compared to 1 year ago.
Compared to 5 years ago, VREX has more shares outstanding
The debt/assets ratio for VREX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.88 indicates that VREX is not a great score, but indicates only limited risk for bankruptcy at the moment.
VREX has a Altman-Z score (1.88) which is in line with its industry peers.
VREX has a debt to FCF ratio of 10.24. This is a negative value and a sign of low solvency as VREX would need 10.24 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 10.24, VREX is doing good in the industry, outperforming 71.81% of the companies in the same industry.
A Debt/Equity ratio of 0.82 indicates that VREX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.82, VREX is doing worse than 71.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | 10.24 | ||
| Altman-Z | 1.88 |
ROIC/WACC0.74
WACC6.84%
2.3 Liquidity
A Current Ratio of 3.51 indicates that VREX has no problem at all paying its short term obligations.
VREX has a better Current ratio (3.51) than 63.30% of its industry peers.
VREX has a Quick Ratio of 1.82. This is a normal value and indicates that VREX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.82, VREX is in line with its industry, outperforming 46.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.00% over the past year.
VREX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 57.78% yearly.
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.28%
3.2 Future
VREX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.20% yearly.
VREX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.86% yearly.
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 13.15, VREX is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of VREX indicates a rather cheap valuation: VREX is cheaper than 89.89% of the companies listed in the same industry.
VREX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.31.
With a Price/Forward Earnings ratio of 14.11, VREX is valued correctly.
VREX's Price/Forward Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 88.30% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, VREX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.15 | ||
| Fwd PE | 14.11 |
4.2 Price Multiples
VREX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VREX is cheaper than 93.09% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VREX indicates a rather cheap valuation: VREX is cheaper than 94.68% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.22 | ||
| EV/EBITDA | 9.81 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.23
EPS Next 2Y8.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VREX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.57
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.29%
Inst Owner Change2.62%
Ins Owners1.66%
Ins Owner Change-1.28%
Market Cap482.47M
Revenue(TTM)N/A
Net Income(TTM)-132.50M
Analysts83.64
Price Target18.16 (56.96%)
Short Float %2.13%
Short Ratio3.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)242.7%
Min EPS beat(2)81.21%
Max EPS beat(2)404.2%
EPS beat(4)4
Avg EPS beat(4)171.36%
Min EPS beat(4)81.21%
Max EPS beat(4)404.2%
EPS beat(8)5
Avg EPS beat(8)76.69%
EPS beat(12)9
Avg EPS beat(12)57.27%
EPS beat(16)12
Avg EPS beat(16)50.06%
Revenue beat(2)2
Avg Revenue beat(2)3.04%
Min Revenue beat(2)1.51%
Max Revenue beat(2)4.57%
Revenue beat(4)3
Avg Revenue beat(4)1.03%
Min Revenue beat(4)-3.1%
Max Revenue beat(4)4.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.55%
Revenue beat(12)5
Avg Revenue beat(12)-0.08%
Revenue beat(16)8
Avg Revenue beat(16)-0.01%
PT rev (1m)2.3%
PT rev (3m)2.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.15 | ||
| Fwd PE | 14.11 | ||
| P/S | 0.59 | ||
| P/FCF | 13.22 | ||
| P/OCF | 8.07 | ||
| P/B | 1.06 | ||
| P/tB | 2 | ||
| EV/EBITDA | 9.81 |
EPS(TTM)0.88
EY7.61%
EPS(NY)0.82
Fwd EY7.09%
FCF(TTM)0.88
FCFY7.57%
OCF(TTM)1.43
OCFY12.39%
SpS19.7
BVpS10.92
TBVpS5.8
PEG (NY)N/A
PEG (5Y)0.23
Graham Number14.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.34% | ||
| ROE | -29.1% | ||
| ROCE | 6.41% | ||
| ROIC | 5.07% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 6.81% | ||
| OM | 7% | ||
| PM (TTM) | N/A | ||
| GM | 34.06% | ||
| FCFM | 4.44% |
ROA(3y)0.83%
ROA(5y)-0.21%
ROE(3y)1.75%
ROE(5y)-0.79%
ROIC(3y)5.22%
ROIC(5y)N/A
ROICexc(3y)6.12%
ROICexc(5y)N/A
ROICexgc(3y)9.48%
ROICexgc(5y)N/A
ROCE(3y)6.6%
ROCE(5y)N/A
ROICexgc growth 3Y-22.06%
ROICexgc growth 5Y-8.2%
ROICexc growth 3Y-20.52%
ROICexc growth 5Y-5.73%
OM growth 3Y-20.79%
OM growth 5Y-6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.37%
F-Score5
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | 10.24 | ||
| Debt/EBITDA | 4.43 | ||
| Cap/Depr | 87.92% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 1.88 | ||
| Cash Conversion | 71.19% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 1.88 |
F-Score5
WACC6.84%
ROIC/WACC0.74
Cap/Depr(3y)70.75%
Cap/Depr(5y)62.44%
Cap/Sales(3y)2.7%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.28%
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.37%
EBIT growth 3Y-21.02%
EBIT growth 5Y-6.03%
EBIT Next Year118.8%
EBIT Next 3Y36.54%
EBIT Next 5YN/A
FCF growth 1Y-31.52%
FCF growth 3Y-35.91%
FCF growth 5Y-17.1%
OCF growth 1Y-23.72%
OCF growth 3Y-20.06%
OCF growth 5Y-8.03%
VAREX IMAGING CORP / VREX FAQ
What is the fundamental rating for VREX stock?
ChartMill assigns a fundamental rating of 4 / 10 to VREX.
Can you provide the valuation status for VAREX IMAGING CORP?
ChartMill assigns a valuation rating of 6 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.
What is the profitability of VREX stock?
VAREX IMAGING CORP (VREX) has a profitability rating of 3 / 10.
Can you provide the financial health for VREX stock?
The financial health rating of VAREX IMAGING CORP (VREX) is 4 / 10.
What is the earnings growth outlook for VAREX IMAGING CORP?
The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to decline by -6.84% in the next year.